Global Blood Therapeutics Reports Positive Phase 3 HOPE Study Results
Global Blood Therapeutics, Inc. (GBT) announced its positive top-line Phase 3 clinical trial data on June 27. The results are from Part A of the Phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS PolymEmerization) Study to evaluate the use of voxelotor as a treatment for sickle cell disease. On the primary endpoint, patients exhibited a statistically significant increase in hemoglobin levels.
Sonal issued an alert at 7:30 am, and the next trade took place for $46.95 at 8:00 am. The stock price exhibited a familiar pattern of spiking on the initial news and then immediately fading back until regular market trading opened at a price of $34. GBT’s stock price pushed higher throughout the day before closing at $44.75, which marks a gain of over 31% from the market open.
If you want to learn more about trading on clinical trial results, visit the Knowledge Center.
To see the latest weekly webinar, you can visit our Live Webinar page.
Subscribe here if you would like to start receiving these signals in real-time and start trading!